GUFICBIO — Gufic Biosciences Share Price
0.000.00%
Last trade - 00:00- IN₹38.26bn
- IN₹41.02bn
- IN₹8.07bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.35 | ||
| Price to Tang. Book | 6.42 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.5 | ||
| EV to EBITDA | 27.53 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 16.65% | ||
| Return on Equity | 16.99% | ||
| Operating Margin | 15.43% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 3,788.37 | 4,876.99 | 7,791.56 | 6,906.21 | 8,066.66 | n/a | n/a | 18.12% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -17.05 | +95.03 | +116.62 | -16.81 | +8.48 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Gufic Biosciences Limited is an India-based company, which is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The Company operates through the pharmaceutical segment. It has pharmaceutical products under categories, such as Criti Care, including Doxific, Micafung, Rabol and Tigefic-Plus; Criticare Life, including Ticofic-200 and Gufivan-500; Ferticare, including Puregraf 75IU 3D, Cetrocare 0.25mg 3D and Follicare 150IU 3D; Spark, including Aznee Duo, Eclin, Flabone, Vipro M and Zad G; Herbal, including Bocomo-Forte, Sallaki-Liniment, Zulcer Cap and Smashit tablet, and Aesthaderm, including Prosil, Moiseta Face Wash and Revanox Serum. Its personal care products include StretchNil, Shapers-Natural Feel, Shaper-DryFeel and RollOn. Its products under active pharmaceutical ingredient (API)/bulk drugs include Micafungin, Anidulafungin, Sulconazole and Everolimus. Its Gufic Stridden includes Irvical and Eve.
Directors
- Jayesh Choksi CHM
- Pranav Choksi CEO
- Devkinandan Roonghta CFO
- Satyen Manikani SVP (48)
- Ami Shah CCO
- Hemal Deasi EDR
- Pankaj Gandhi EDR
- Dilip Ghosh EDR (68)
- Balram Singh NED (60)
- Anu Aurora IND
- Gopal Daptari IND
- Shrirang Vaidya IND (61)
- Sharat Gandhi NID
- Shreyas Patel NID
- Rabi Sahoo NID
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 23rd, 1984
- Public Since
- October 19th, 2004
- No. of Shareholders
- 35,327
- No. of Employees
- 1,448
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 100,277,506
- Address
- 1st to 4th Floor,, MUMBAI, 400057
- Web
- https://gufic.com/
- Phone
- +91 2267261000
- Auditors
- Mittal Agarwal & Company
Upcoming Events for GUFICBIO
Q1 2026 Gufic Biosciences Ltd Earnings Release
Gufic Biosciences Ltd Annual Shareholders Meeting
Similar to GUFICBIO
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Gufic Biosciences share price?
As of Today at 20:58 UTC, shares in Gufic Biosciences are trading at IN₹363.75. This share price information is delayed by 15 minutes.
How has the Gufic Biosciences share price performed this year?
Shares in Gufic Biosciences last closed at IN₹363.75 and the price had moved by +13.41% over the past 365 days. In terms of relative price strength the Gufic Biosciences share price has outperformed the S&P BSE 100 Index by +6.83% over the past year.
What are the analyst and broker recommendations for Gufic Biosciences?
The overall consensus recommendation for Gufic Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Gufic Biosciences dividend yield?
The Gufic Biosciences dividend yield is 0.03% based on the trailing twelve month period.
Does Gufic Biosciences pay a dividend?
Last year, Gufic Biosciences paid a total dividend of IN₹0.10, and it currently has a trailing dividend yield of 0.03%. We do not have any data on when Gufic Biosciences is to next pay dividends.
When does Gufic Biosciences next pay dividends?
We do not have data on when Gufic Biosciences is to next pay dividends. The historic dividend yield on Gufic Biosciences shares is currently 0.03%.
How do I buy Gufic Biosciences shares?
To buy shares in Gufic Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Gufic Biosciences?
As of the previous close price of IN₹363.75, shares in Gufic Biosciences had a market capitalisation of IN₹38.26bn.
Where are Gufic Biosciences shares listed?
Here are the trading details for Gufic Biosciences:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: GUFICBIO
What kind of share is Gufic Biosciences?
Based on an overall assessment of its quality, value and momentum Gufic Biosciences is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Gufic Biosciences share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Gufic Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Gufic Biosciences. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -11.36%.
As of the last closing price of IN₹363.75, shares in Gufic Biosciences were trading -8.42% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Gufic Biosciences PE Ratio?
The Gufic Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹363.75.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Gufic Biosciences?
Gufic Biosciences' management team is headed by:
- Jayesh Choksi - CHM
- Pranav Choksi - CEO
- Devkinandan Roonghta - CFO
- Satyen Manikani - SVP
- Ami Shah - CCO
- Hemal Deasi - EDR
- Pankaj Gandhi - EDR
- Dilip Ghosh - EDR
- Balram Singh - NED
- Anu Aurora - IND
- Gopal Daptari - IND
- Shrirang Vaidya - IND
- Sharat Gandhi - NID
- Shreyas Patel - NID
- Rabi Sahoo - NID